Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 1965-1976

  Stein, Brady L ^a   Moliterno, Alison R ^b   Tiu, Ramón V ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Burden of disease; JAK2; Myeloproliferative neoplasms; Polycythemia vera; Quality of life; Symptoms

Indexed keywords

HYDROXYUREA; INTERFERON; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PIPOBROMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; RUXOLITINIB;

BLEEDING; FATIGUE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MORTALITY; POLYCYTHEMIA VERA; PRURITUS; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SPLENOMEGALY; THROMBOSIS; COMPLICATION; COST OF ILLNESS; DISEASE COURSE; ECONOMICS; EXPERIMENTAL THERAPY; GENETICS; HEMORRHAGIC DISORDERS; LEUKEMIA, MYELOID, ACUTE; MISSENSE MUTATION; MULTIMODALITY CANCER THERAPY; NEOPLASMS, SECOND PRIMARY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY MYELOFIBROSIS; THROMBOPHILIA;

CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; COST OF ILLNESS; DISEASE PROGRESSION; FATIGUE; HEALTH CARE COSTS; HEMORRHAGIC DISORDERS; HUMANS; HYDROXYUREA; INTERFERONS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MUTATION, MISSENSE; NEOPLASMS, SECOND PRIMARY; PIPOBROMAN; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY OF LIFE; THERAPIES, INVESTIGATIONAL; THROMBOPHILIA;

EID: 84919724794     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2205-y     Document Type: Review

References (101)

1. Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176–2184. doi:10.1182/blood-2013-03-460154
2. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6(4):372–375
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397. doi:10.1016/j.ccr.2005.03.023
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790. doi:10.1056/NEJMoa051113
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148. doi:10.1038/nature03546
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome P (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061. doi:10.1016/S0140-6736(05)71142-9
7. Tefferi A (2013) Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(6):507–516. doi:10.1002/ajh.23417
8. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574–1579. doi:10.1038/leu.2010.148
9. Barbui T, Thiele J, Vannucchi AM, Tefferi A (2014) Rethinking the diagnostic criteria of polycythemia vera. Leukemia. doi:10.1038/leu.2013.380
10. Cassinat B, Laguillier C, Gardin C, de Beco V, Burcheri S, Fenaux P, Chomienne C, Kiladjian JJ, Group PV-N (2008) Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 22(2):452–453
11. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera I (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114–124. doi:10.1056/NEJMoa035572
12. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, Cyto-Pv Collaborative Group (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33. doi:10.1056/NEJMoa1208500
13. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065–3072. doi:10.1182/blood-2008-03-143537
14. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418–5424
15. Mehta J, Wang H, Iqbal SU, Mesa R (2014) Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 55(3):595–600. doi:10.3109/10428194.2013.813500
16. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, Luigia Randi M, Betozzi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Mullauer L, Ruggeri M, Rambaldi A, Tefferi A (2014) Masked polycythemia vera (mPV): results of an international study. Am J Hematol 89(1):52–54. doi:10.1002/ajh.23585
17. Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR (2013) Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 54(9):1989–1995. doi:10.3109/10428194.2012.759656
18. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T, ECLAP Investigators (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7):2664–2670. doi:10.1182/blood-2004-09-3426
19. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881
20. Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR (2010) Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95(7):1090–1097. doi:10.3324/haematol.2009.014407
21. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109(1):68–76. doi:10.1002/cncr.22365
22. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103. doi:10.1200/JCO.2012.42.3863
23. Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegard G, Andreasson B (2012) Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma 53(3):441–444. doi:10.3109/10428194.2011.619608
24. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118(2):401–408. doi:10.1182/blood-2011-01-328955
25. Siegel FP, Tauscher J, Petrides PE (2013) Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 88(8):665–669. doi:10.1002/ajh.23474
26. Diehn F, Tefferi A (2001) Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 115(3):619–621. doi:10.1046/j.1365-2141.2001.03161.x
27. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S (1993) Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 43(4):316–318
28. Geyer HL, Emanuel RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA (2014) Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123(24):3803–3810. doi:10.1182/blood-2013-09-527903
29. Scherber R, Dueck AC, Kiladjian JJ, Slot SS, Zweegman S, Boekhorst P, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Greiesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Roy L, Cahn JY, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi A, Passamonti F, Andreasson B, Ferarri M, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA (HU/IFNa/Aspirin) Conventional therapeutic options have limited impact on MPN symptoms: insights from a prospective analysis of the MPN-SAF. In: European Hematology Association, Amsterdam, Netherlands, June 14–17 2012. p abstract 366
30. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G, Nordic Study Group for Myeloproliferative Disorders (2006) A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106(11):2397–2405. doi:10.1002/cncr.21900
31. Merup M, Aberg W, Lofvenberg E, Svensson E, Engman K, Paul C, Gardulf A (2002) Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol 41(1):50–55
32. Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P (2013) Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma 54(10):2226–2230. doi:10.3109/10428194.2013.766732
33. Emanuel RM, Senyak Z, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA (2013) The MPN Fatigue Project: stage 1 results of the MPN forum internet-based survey among 879 MPN patients [abstract]. Blood 122:1595
34. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T, MPD Research Consortium (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952–1959. doi:10.1038/sj.leu.2404854
35. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G (2012) Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 13(10):1020–1024
36. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 23(6):1228–1236. doi:10.1200/JCO.2005.06.050
37. Karve S, Price GL, Davis KL, Pohl GM, Walgren RA (2012) Health care utilization and associated costs in elderly persons with non-CML myeloproliferative neoplasms: real-world evidence from a United States Medicare population [abstract 4273]. Blood 120(21):4273
38. Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R (2014) Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma, in press
39. Price GL, Pohl GM, Xie J, Walgren RA (2011) A retrospective observational comparison of comorbidities between myeloproliferative neoplasm (MPN) patients and matched controls in a commercially insured US population [abstract 3140]. Blood 118(21):2060
40. Reikvam H, Tiu RV (2012) Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 26(4):563–571. doi:10.1038/leu.2011.314
41. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia (1995). Ann Intern Med 123(9):656–664. doi:10.7326/0003-4819-123-9-199511010-00003
42. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232. doi:10.1200/JCO.2005.07.062
43. Finazzi G, Barbui T (2007) How I treat patients with polycythemia vera. Blood 109(12):5104–5111
44. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921–4928. doi:10.1182/blood-2011-09-376517
45. Pieri L, Guglielmelli P, Primignani M, Brambilla C, Randi ML, Santarossa C, Cazzola M, Rumi E, Cervantes F, Ellis M, Chen F, Tripathi D, Rajoriya N, Barbui T, Delaini F, De Stefano V, Rossi E, Betti S, Specchia G, Ricco A, Gisslinger H, Gisslinger B, Vianelli N, Polverelli N, Ruggeri M, Girodon F, Tefferi A, Vannucchi AM (2013) Splanchnic vein thrombosis associated with myeloproliferative neoplasms. A study of the IWG-MRT in 475 subjects [abstract]. Blood 122(21):1582
46. Polednak AP (2012) Recent decline in the U.S. death rate from myeloproliferative neoplasms, 1999–2006. Cancer Epidemiol 36(2):133–136. doi:10.1016/j.canep.2011.05.016
47. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446–2452. doi:10.1182/blood-2006-08-042515
48. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T, Gimema Chronic Myeloproliferative Neoplasms Working Party (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85(2):97–100. doi:10.1002/ajh.21593
49. Stein BL, Rademaker A, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis 2011:874146. doi:10.1155/2011/874146
50. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A, (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96(2):315–318. doi:10.3324/haematol.2010.031070
51. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91(2):169–175
52. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F (2009) Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 84(2):102–108
53. Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112(10):4061–4068
54. Han Y, Zhao S, Zhang W, Cen J, Zhang W, Qiu H, Sun A, Wang Z, Ruan C (2013) Clinical significance of circulating microparticles in Ph-myeloproliferative neoplasms (MPN). Blood (ASH Annual Meeting Abstracts) 122 (21):abstract 2368
55. Tan X, Shi J, Fu Y, Gao C, Yang X, Li J, Wang W, Hou J, Li H, Zhou J (2013) Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost 109(6):1025–1032. doi:10.1160/TH12-11-0811
56. Passamonti F (2012) How I treat polycythemia vera. Blood 120(2):275–284. doi:10.1182/blood-2012-02-366054
57. Squizzato A, Romualdi E, Passamonti F, Middeldorp S (2013) Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev 4:CD006503. doi:10.1002/14651858.CD006503.pub3
58. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132–1136
59. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia S (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45
60. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR (1997) From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34(1):17–23
61. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29(29):3907–3913. doi:10.1200/JCO.2011.36.0792
62. Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F, Angona A, Gomez M, Muina B, Guillen H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363–1369. doi:10.1182/blood-2011-10-387787
63. Hernandez-Boluda JC, Alvarez-Larran A, Gomez M, Angona A, Amat P, Bellosillo B, Martinez-Aviles L, Navarro B, Teruel A, Martinez-Ruiz F, Besses C (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152(1):81–88
64. McMahon B, Stein BL (2013) Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 39(1):101–111
65. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European L (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761–770. doi:10.1200/JCO.2010.31.8436
66. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis R, Treatment (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438
67. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, Del Curto C, Pietra D, Vanelli L, Bernasconi P, Pascutto C, Cazzola M, Morra E, Lazzarino M (2008) A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111(7):3383–3387
68. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Mullauer L, Finazzi G, Carobbio A, Gianatti A, Ruggeri M, Nichele I, D’Amore E, Rambaldi A, Tefferi A (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10):2239–2241. doi:10.1182/blood-2011-11-393819
69. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708
70. Vannucchi AM (2011) Management of myelofibrosis. Hematol Am Soc Hematol Educ Program 2011:222–230. doi:10.1182/asheducation-2011.1.222
71. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755–761. doi:10.1016/j.amjmed.2004.06.032
72. Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E, Canevari A, Castelli G, Merante S, Bernasconi C (2000) Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 85(10):1011–1018
73. Kanitakis J, Arbona-Vidal E, Faure M (2012) Porokeratosis in patients with polycythemia rubra vera: a new side effect of hydroxyurea? J Eur Acad Dermatol Venereol 26(8):1040–1041. doi:10.1111/j.1468-3083.2011.04202.x
74. Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Bjorkholm M (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30(24):2995–3001. doi:10.1200/JCO.2012.42.1925
75. Albizua E, Gallardo M, Barrio S, Rapado I, Jimenez A, Ayala R, Rueda D, Sanchez-Espiridion B, Puigdecanet E, Espinet B, Florensa L, Besses C, Martinez-Lopez J (2011) Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Ann Hematol 90(8):939–946. doi:10.1007/s00277-011-1179-2
76. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148(6):961–963. doi:10.1111/j.1365-2141.2009.08019.x
77. Silver RT, Bourla MH, Vandris K, Fruchtman S, Spivak JL, Feldman EJ, Salvado AJ (2012) Treatment of polycythemia vera with imatinib mesylate. Leuk Res 36(2):156–162. doi:10.1016/j.leukres.2011.09.001
78. Franca ER, Teixeira MA, Matias Kde F, Antunes DE, Braz Rde A, Silva CE (2011) Cutaneous effects after prolonged use of hydroxyurea in polycythemia vera. An Bras Dermatol 86(4):751–754. doi:10.1590/S0365-05962011000400019
79. Najean Y, Rain JD (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90(9):3370–3377
80. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513–520. doi:10.1002/cncr.28441
81. Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, Pogliani EM, Olimpieri OM, Fioritoni G, Musolino C, Cilloni D, Sivera P, Barosi G, Finazzi MC, Di Tollo S, Demuth T, Barbui T, Rambaldi A (2013) A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol 161(5):688–694. doi:10.1111/bjh.12332
82. Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison C, Pane F, Zachee P, Mesa RA, He S, Jones M, Garrett WM, Li J, Pirron U, Lawniczek T, Vannucchi AM (2014) Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. J Clin Oncol 32 (5s):abstract 7026
83. Verstovsek S, Mesa RA, Salama ME, Giles JLK, Pitou C, Zimmermann AH, Price GL, Walgreen RA, Prchal J (2013) Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 122(21):665
84. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13(4):311–320. doi:10.1016/j.ccr.2008.02.009
85. Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, Moliterno A (2014) Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. Br J Haematol 164(1):83–93. doi:10.1111/bjh.12607
86. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC (2012) Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 53(1):123–129. doi:10.3109/10428194.2011.597905
87. Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lubbert M, Dello Sbarba P, Santini V (2008) Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 27(12):1767–1778. doi:10.1038/sj.onc.1210820
88. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D’Urzo C, Vannucchi AM, Barosi G, Barbui T (2010) A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150(4):446–455. doi:10.1111/j.1365-2141.2010.08266.x
89. Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Lofvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC (2013) A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol 162(4):498–508. doi:10.1111/bjh.12416
90. Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107(3):451–458. doi:10.1002/cncr.22026
91. Silver RT (1988) Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 2(8607):403. doi:10.1016/S0140-6736(88)92881
92. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G (2005) Side effects of interferon-alpha therapy. Pharm World Sci 27(6):423–431. doi:10.1007/s11096-005-1319-7
93. Stein BL, Tiu RV (2013) Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res 33(4):145–153. doi:10.1089/jir.2012.0120
94. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S (2006) Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 32(4 Pt 2):409–416. doi:10.1055/s-2006-942761
95. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S (2013) Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 122(6):893–901. doi:10.1182/blood-2012-07-442012
96. Silver RT, Kiladjian J-J, Hasselbalch HC (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 6(1):49–58. doi:10.1586/ehm.12.69
97. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14–22. doi:10.1038/sj.leu.2404955
98. Johansson PL, Safai-Kutti S, Kutti J (2005) An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 129(5):701–705
99. Alvarez-Larran A, Ancochea A, Angona A, Pedro C, Garcia-Pallarols F, Martinez-Aviles L, Bellosillo B, Besses C (2012) Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 97(11):1704–1707. doi:10.3324/haematol.2012.067348
100. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ (2013) Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 122(11):1881–1886. doi:10.1182/blood-2013-06-508416
101. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113(20):4829–4833